<![CDATA[Hansa Biopharma — Maj 2023]]>Nogen køber kraftigt op i Hansa de sidste par handelsdage. Lad os håbe det var vendingen 🙂

]]>https://dev.proinvestor.com/forum/topic/400738/hansa-biopharma-maj-2023RSS for NodeSat, 06 Jun 2026 12:13:28 GMTMon, 08 May 2023 06:36:19 GMT60<![CDATA[Reply to Hansa Biopharma — Maj 2023 on Wed, 31 May 2023 03:45:46 GMT]]>Godmorgen 🙂

]]>https://dev.proinvestor.com/forum/post/8006713https://dev.proinvestor.com/forum/post/8006713Wed, 31 May 2023 03:45:46 GMT<![CDATA[Reply to Hansa Biopharma — Maj 2023 on Tue, 30 May 2023 13:48:46 GMT]]>Hansa Biopharma – Deep Dive into other indications for Imlifidase - 30.05.2023

(HC Andersen Capital)

]]>https://dev.proinvestor.com/forum/post/8006710https://dev.proinvestor.com/forum/post/8006710Tue, 30 May 2023 13:48:46 GMT<![CDATA[Reply to Hansa Biopharma — Maj 2023 on Tue, 30 May 2023 13:48:33 GMT]]>Hansa announces first patient dosed with imlifidase in a global pivotal phase 3 trial in anti-glomerular basement membrane (anti-GBM) disease

Link Preview Image
Hansa announces first patient dosed with imlifidase in a global pivotal phase 3 trial in anti-glomerular basement membrane (anti-GBM) disease | Hansa Biopharma

favicon

(www.hansabiopharma.com)

(30 May 2023, 08:00)

]]>https://dev.proinvestor.com/forum/post/8006716https://dev.proinvestor.com/forum/post/8006716Tue, 30 May 2023 13:48:33 GMT<![CDATA[Reply to Hansa Biopharma — Maj 2023 on Tue, 30 May 2023 03:24:26 GMT]]>Godmorgen 🙂 ja så er kursen igen presset tilbage et langt sejt træk med denne her

]]>https://dev.proinvestor.com/forum/post/8006715https://dev.proinvestor.com/forum/post/8006715Tue, 30 May 2023 03:24:26 GMT<![CDATA[Reply to Hansa Biopharma — Maj 2023 on Sat, 27 May 2023 09:00:59 GMT]]>RBC Capital Markets har sat et nyt Sarepta Therapeutics kursmål på USD 218 med anbefalingen Outperform ... RBC ser en smule negativt på meldingen fra FDA men anbefaler dog at købe på et tilbagefald.

https://pbs.twimg.com/media/FxA6F9NWIAI6SCZ?format=png&name=900x900

]]>https://dev.proinvestor.com/forum/post/8006712https://dev.proinvestor.com/forum/post/8006712Sat, 27 May 2023 09:00:59 GMT<![CDATA[Reply to Hansa Biopharma — Maj 2023 on Sat, 27 May 2023 09:00:51 GMT]]>EMBARK toplinje-resultater forventes i fjerde kvartal.

]]>https://dev.proinvestor.com/forum/post/8006708https://dev.proinvestor.com/forum/post/8006708Sat, 27 May 2023 09:00:51 GMT<![CDATA[Reply to Hansa Biopharma — Maj 2023 on Sat, 27 May 2023 09:00:44 GMT]]>UPDATE: FDA needs more time for Sarepta's DMD gene therapy—spurring a deja vu of Exondys 51 (May 24, 2023 08:39am)

Just a moment...

favicon

(www.fiercebiotech.com)

"The FDA needs a wee bit more time to consider the approval of Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy (DMD), however, the agency has indicated an accelerated approval is likely in a restricted age group."

]]>https://dev.proinvestor.com/forum/post/8006709https://dev.proinvestor.com/forum/post/8006709Sat, 27 May 2023 09:00:44 GMT<![CDATA[Reply to Hansa Biopharma — Maj 2023 on Fri, 26 May 2023 03:20:24 GMT]]>Godmorgen 🙂

]]>https://dev.proinvestor.com/forum/post/8006706https://dev.proinvestor.com/forum/post/8006706Fri, 26 May 2023 03:20:24 GMT<![CDATA[Reply to Hansa Biopharma — Maj 2023 on Thu, 25 May 2023 03:17:18 GMT]]>Godmorgen 🙂 ja tålmodigheden bliver tit sat på prøve i denne her case det har været længe undervejs efterhånden en lang lang rejse men vi holder ved 🙂

]]>https://dev.proinvestor.com/forum/post/8006714https://dev.proinvestor.com/forum/post/8006714Thu, 25 May 2023 03:17:18 GMT<![CDATA[Reply to Hansa Biopharma — Maj 2023 on Wed, 24 May 2023 18:36:31 GMT]]>Så må vi jo væbne os med lidt yderligere tålmodighed. Men det går vel nok endda. 😉

]]>https://dev.proinvestor.com/forum/post/8006704https://dev.proinvestor.com/forum/post/8006704Wed, 24 May 2023 18:36:31 GMT<![CDATA[Reply to Hansa Biopharma — Maj 2023 on Wed, 24 May 2023 14:18:10 GMT]]>.... Sarepta will remain in a quiet period for the duration of the BLA review.

]]>https://dev.proinvestor.com/forum/post/8006707https://dev.proinvestor.com/forum/post/8006707Wed, 24 May 2023 14:18:10 GMT<![CDATA[Reply to Hansa Biopharma — Maj 2023 on Wed, 24 May 2023 14:17:16 GMT]]>.... CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 24, 2023-- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today provided the following update on the Biologics License Application (BLA) for SRP-9001 (delandistrogene moxeparvovec), which is currently under review for the treatment of ambulant individuals with Duchenne muscular dystrophy (DMD) who have a confirmed mutation of the DMD gene.

]]>https://dev.proinvestor.com/forum/post/8006711https://dev.proinvestor.com/forum/post/8006711Wed, 24 May 2023 14:17:16 GMT<![CDATA[Reply to Hansa Biopharma — Maj 2023 on Wed, 24 May 2023 14:17:07 GMT]]>Sarepta Therapeutics Announces Update on Regulatory Review of SRP-9001

https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-update-regulatory-review-srp-9001?_ga=2.101235842.2073829004.1684944923-1758491174.1683956918

(05/24/23 8:00 AM EDT)

New regulatory action date is June 22, 2023 ...

]]>https://dev.proinvestor.com/forum/post/8006705https://dev.proinvestor.com/forum/post/8006705Wed, 24 May 2023 14:17:07 GMT<![CDATA[Reply to Hansa Biopharma — Maj 2023 on Wed, 24 May 2023 03:37:35 GMT]]>Godmorgen 🙂

]]>https://dev.proinvestor.com/forum/post/8006700https://dev.proinvestor.com/forum/post/8006700Wed, 24 May 2023 03:37:35 GMT<![CDATA[Reply to Hansa Biopharma — Maj 2023 on Tue, 23 May 2023 12:35:45 GMT]]>@LP90 - Okay!

]]>https://dev.proinvestor.com/forum/post/8006703https://dev.proinvestor.com/forum/post/8006703Tue, 23 May 2023 12:35:45 GMT<![CDATA[Reply to Hansa Biopharma — Maj 2023 on Tue, 23 May 2023 03:36:06 GMT]]>Exitnu jeps holder stadig og køber på dip (har ret mange efterhånden både i fri og pension 🙂

]]>https://dev.proinvestor.com/forum/post/8006699https://dev.proinvestor.com/forum/post/8006699Tue, 23 May 2023 03:36:06 GMT<![CDATA[Reply to Hansa Biopharma — Maj 2023 on Tue, 23 May 2023 03:34:53 GMT]]>Godmorgen 🙂

]]>https://dev.proinvestor.com/forum/post/8006701https://dev.proinvestor.com/forum/post/8006701Tue, 23 May 2023 03:34:53 GMT<![CDATA[Reply to Hansa Biopharma — Maj 2023 on Mon, 22 May 2023 13:34:44 GMT]]>@LP90 - godt du stadig holder ved 🙂

]]>https://dev.proinvestor.com/forum/post/8006697https://dev.proinvestor.com/forum/post/8006697Mon, 22 May 2023 13:34:44 GMT<![CDATA[Reply to Hansa Biopharma — Maj 2023 on Mon, 22 May 2023 03:35:25 GMT]]>Godmorgen 🙂

]]>https://dev.proinvestor.com/forum/post/8006695https://dev.proinvestor.com/forum/post/8006695Mon, 22 May 2023 03:35:25 GMT<![CDATA[Reply to Hansa Biopharma — Maj 2023 on Sun, 21 May 2023 12:29:01 GMT]]>2 år gammel artikel, men meget interessant omkring Gene Therapy udbredelse og udfordringerhttps://static1.squarespace.com/static/5b5f666c9772ae3d286108fa/t/60bfd0b60c9d4d5d831e0298/1623183547382/BBLSA_WhitePaper-GeneTherapy-6-8-21.pdf

]]>https://dev.proinvestor.com/forum/post/8006702https://dev.proinvestor.com/forum/post/8006702Sun, 21 May 2023 12:29:01 GMT<![CDATA[Reply to Hansa Biopharma — Maj 2023 on Sun, 21 May 2023 07:27:17 GMT]]>"Hansa Biopharma will be eligible to receive up to USD 400 million in milestones from Sarepta Therapeutics plus up to midteens in royalty payments and sales of imlifidase"

Mandag d. 29 maj - kun lidt over en uge tilbage 🙂

]]>https://dev.proinvestor.com/forum/post/8006698https://dev.proinvestor.com/forum/post/8006698Sun, 21 May 2023 07:27:17 GMT<![CDATA[Reply to Hansa Biopharma — Maj 2023 on Fri, 19 May 2023 05:24:56 GMT]]>According to Fierce Biotech, expectations in DMD are high with SRP-9001 potentially be one of the biggest biotech product launches in 2023 with annual sales of more than USD 2 billion in less than five years". https://proinvestor.com/boards/112647/

]]>https://dev.proinvestor.com/forum/post/8006694https://dev.proinvestor.com/forum/post/8006694Fri, 19 May 2023 05:24:56 GMT<![CDATA[Reply to Hansa Biopharma — Maj 2023 on Fri, 19 May 2023 05:24:28 GMT]]>Bioinvest..."Hansa Biopharma's enzyme cleaving technology imlifidase may potentially be used as a pre-treatment to SRP-9001 in up to 14% of the DMD patient population and if successful in both DMD and LGMD Hansa Biopharma will be eligible to receive up to USD 400 million in milestones from Sarepta Therapeutics plus up to midteens in royalty payments and sales of imlifidase.

]]>https://dev.proinvestor.com/forum/post/8006693https://dev.proinvestor.com/forum/post/8006693Fri, 19 May 2023 05:24:28 GMT<![CDATA[Reply to Hansa Biopharma — Maj 2023 on Fri, 19 May 2023 03:21:21 GMT]]>Godmorgen 🙂

]]>https://dev.proinvestor.com/forum/post/8006691https://dev.proinvestor.com/forum/post/8006691Fri, 19 May 2023 03:21:21 GMT